# Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

> **NCT02279953** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 151 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine 10-20 mg
- **DRUG:** Placebo
- **DRUG:** SSRI

## Key facts

- **NCT ID:** NCT02279953
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2017-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279953, "Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02279953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*